{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T09:19:11Z","timestamp":1770887951542,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>COVID-19 has been associated with high mortality in patients treated with Chimeric Antigen Receptor (CAR) T-cell therapy for hematologic malignancies. Here, we investigated whether the outcome has improved over time with the primary objective of assessing COVID-19-attributable mortality in the Omicron period of 2022 compared to previous years. Data for this multicenter study were collected using the MED-A and COVID-19 report forms developed by the EBMT. One-hundred-eighty patients were included in the analysis, 39 diagnosed in 2020, 35 in 2021 and 106 in 2022. The median age was 58.9 years (min-max: 5.2\u201378.4). There was a successive decrease in COVID-19-related mortality over time (2020: 43.6%, 2021: 22.9%, 2022: 7.5%) and in multivariate analysis year of infection was the strongest predictor of survival (<jats:italic>p<\/jats:italic>\u2009=\u20090.0001). Comparing 2022 with 2020\u20132021, significantly fewer patients had lower respiratory symptoms (21.7% vs 37.8%, <jats:italic>p<\/jats:italic>\u2009=\u20090.01), needed oxygen support (25.5% vs 43.2%, <jats:italic>p<\/jats:italic>\u2009=\u20090.01), or were admitted to ICU (5.7% vs 33.8%, <jats:italic>p<\/jats:italic>\u2009=\u20090.0001). Although COVID-19-related mortality has decreased over time, CAR T-cell recipients remain at higher risk for complications than the general population. Consequently, vigilant monitoring for COVID-19 in patients undergoing B-cell-targeting CAR T-cell treatment is continuously recommended ensuring optimal prevention of infection and advanced state-of-the art treatment when needed.<\/jats:p>","DOI":"10.1038\/s41375-024-02336-1","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T15:10:32Z","timestamp":1721747432000},"page":"1985-1991","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP) and the European Hematology Association (EHA) Lymphoma Group"],"prefix":"10.1038","volume":"38","author":[{"given":"Anne Mea","family":"Spanjaart","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per","family":"Ljungman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gloria","family":"Tridello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juana","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuria","family":"Martinez-Cibri\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1038-5197","authenticated-orcid":false,"given":"Pere","family":"Barba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mi","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1908-5596","authenticated-orcid":false,"given":"Lucia","family":"Lopez-Corral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7908-0063","authenticated-orcid":false,"given":"Joaquin","family":"Martinez-Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christelle","family":"Ferra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Di Blasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herv\u00e9","family":"Ghesquieres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3924-8578","authenticated-orcid":false,"given":"Pim","family":"Mutsaers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9059-0929","authenticated-orcid":false,"given":"Friso","family":"Calkoen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margot","family":"Jak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0214-3219","authenticated-orcid":false,"given":"Jaap","family":"van Doesum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joost S. P.","family":"Vermaat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjolein","family":"van der Poel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4257-5980","authenticated-orcid":false,"given":"Johan","family":"Maertens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimiliano","family":"Gambella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Metafuni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Ciceri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Saccardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6439-0795","authenticated-orcid":false,"given":"Emma","family":"Nicholson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleni","family":"Tholouli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Collin","family":"Matthew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Potter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Bloor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Besley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Roddie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6327-9366","authenticated-orcid":false,"given":"Keith","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnon","family":"Nagler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Campos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soeren Lykke","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7034-769X","authenticated-orcid":false,"given":"Frantisek","family":"Folber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Bader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1799-5927","authenticated-orcid":false,"given":"Jurgen","family":"Finke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5103-9966","authenticated-orcid":false,"given":"Nicolaus","family":"Kroger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Knelange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8189-5779","authenticated-orcid":false,"given":"Rafael","family":"de La Camara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8904-3802","authenticated-orcid":false,"given":"Marie Jos\u00e9","family":"Kersten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0167-6021","authenticated-orcid":false,"given":"Stephan","family":"Mielke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,23]]},"reference":[{"key":"2336_CR1","doi-asserted-by":"publisher","first-page":"3585","DOI":"10.1038\/s41375-021-01466-0","volume":"35","author":"AM Spanjaart","year":"2021","unstructured":"Spanjaart AM, Ljungman P, de La Camara R, Tridello G, Ortiz-Maldonado V, Urbano-Ispizua A, et al. Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group. Leukemia. 2021;35:3585\u20138.","journal-title":"Leukemia"},{"key":"2336_CR2","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1182\/bloodadvances.2021005616","volume":"6","author":"A Busca","year":"2022","unstructured":"Busca A, Salmanton-Garc\u00eda J, Corradini P, Marchesi F, Cabirta A, Di Blasi R, et al. COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP. Blood Adv. 2022;6:2427\u201333.","journal-title":"Blood Adv"},{"key":"2336_CR3","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1056\/NEJMoa2118946","volume":"386","author":"Y Goldberg","year":"2022","unstructured":"Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman LS, Ash N, et al. Protection and waning of natural and hybrid immunity to SARS-CoV-2. N. Engl J Med. 2022;386:2201\u201312.","journal-title":"N. Engl J Med"},{"key":"2336_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.envres.2022.112911","volume":"209","author":"S Pilz","year":"2022","unstructured":"Pilz S, Theiler-Schwetz V, Trummer C, Krause R, Ioannidis JPA. SARS-CoV-2 reinfections: overview of efficacy and duration of natural and hybrid immunity. Environ Res. 2022;209:112911.","journal-title":"Environ Res"},{"key":"2336_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33498-0","volume":"13","author":"FP Lyngse","year":"2022","unstructured":"Lyngse FP, Kirkeby CT, Denwood M, Christiansen LE, M\u00f8lbak K, M\u00f8ller CH, et al. Household transmission of SARS-CoV-2 Omicron variant of concern subvariants BA.1 and BA.2 in Denmark. Nat Commun. 2022;13:5760.","journal-title":"Nat Commun"},{"key":"2336_CR6","first-page":"386","volume":"17","author":"RP Bhattacharyya","year":"2022","unstructured":"Bhattacharyya RP, Hanage WP. Challenges in inferring intrinsic severity of the SARS-CoV-2 omicron variant. N Engl J Med. 2022;17:386.e14","journal-title":"N Engl J Med"},{"key":"2336_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1125824","volume":"14","author":"P Ljungman","year":"2023","unstructured":"Ljungman P, Tridello G, Pi\u00f1ana JL, Ciceri F, Sengeloev H, Kulagin A, et al. Improved outcomes over time and higher mortality in CMV seropositive allogeneic stem cell transplantation patients with COVID-19; An infectious disease working party study from the European Society for Blood and Marrow Transplantation registry. Front Immunol. 2023;14:1125824.","journal-title":"Front Immunol"},{"key":"2336_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104700","volume":"94","author":"P Chen","year":"2023","unstructured":"Chen P, Bergman P, Blennow O, Hansson L, Mielke S, Nowak P, et al. Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a one-year follow-up of the prospective clinical trial COVAXID. EBioMedicine. 2023;94:104700.","journal-title":"EBioMedicine"},{"key":"2336_CR9","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1053\/j.seminhematol.2022.11.001","volume":"59","author":"S Haggenburg","year":"2022","unstructured":"Haggenburg S, Hofsink Q, Rutten CE, Nijhof IS, Hazenberg MD, Goorhuis A. SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies. Semin Hematol. 2022;59:192\u20137.","journal-title":"Semin Hematol"},{"key":"2336_CR10","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1001\/jamaoncol.2022.3227","volume":"8","author":"S Haggenburg","year":"2022","unstructured":"Haggenburg S, Hofsink Q, Lissenberg-Witte BI, Broers AEC, van Doesum JA, van Binnendijk RS, et al. COBRA KAI Study Team. Antibody Response in Immunocompromised Patients With Hematologic Cancers Who Received a 3-Dose mRNA-1273 Vaccination Schedule for COVID-19. JAMA Oncol. 2022;8:1477\u201383.","journal-title":"JAMA Oncol"},{"key":"2336_CR11","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1182\/blood.2021012769","volume":"138","author":"B Dhakal","year":"2021","unstructured":"Dhakal B, Abedin S, Fenske T, Chhabra S, Ledeboer N, Hari P, et al. Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy. Blood. 2021;138:1278\u201381.","journal-title":"Blood"},{"key":"2336_CR12","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1038\/s41375-023-01938-5","volume":"37","author":"S Cesaro","year":"2023","unstructured":"Cesaro S, Mikulska M, Hirsch HH, Styczynski J, Meylan S, Cordonnier C, et al. Update of recommendations for the management of COVID-19 in patients with haematological malignancies, haematopoietic cell transplantation and CAR T therapy, from the 2022 European Conference on Infections in Leukaemia (ECIL 9). Leukemia. 2023;37:1933\u20138.","journal-title":"Leukemia"},{"key":"2336_CR13","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","volume":"33","author":"PJ Hayden","year":"2022","unstructured":"Hayden PJ, Roddie C, Bader P, Basak GW, Bonig H, Bonini C, et al. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann Oncol. 2022;33:259\u201375.","journal-title":"Ann Oncol"},{"key":"2336_CR14","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1182\/blood.2022017257","volume":"140","author":"L Pagano","year":"2022","unstructured":"Pagano L, Salmanton-Garc\u00eda J, Marchesi F, Blennow O, Gomes da Silva M, Glenth\u00f8j A, et al. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey. Blood. 2022;140:2773\u201387.","journal-title":"Blood"},{"key":"2336_CR15","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1182\/bloodadvances.2022009578","volume":"7","author":"JA van Doesum","year":"2023","unstructured":"van Doesum JA, Salmanton-Garc\u00eda J, Marchesi F, Di Blasi R, Falces-Romero I, Cabirta A, et al. Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post-CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey. Blood Adv. 2023;7:2645\u201355.","journal-title":"Blood Adv"},{"key":"2336_CR16","doi-asserted-by":"publisher","first-page":"e005957","DOI":"10.1136\/jitc-2022-005957","volume":"11","author":"KO McNerney","year":"2023","unstructured":"McNerney KO, Richards RM, Aguayo-Hiraldo P, Calkoen FG, Talano JA, Moskop A, et al. SARS-CoV-2 infections in pediatric and young adult recipients of chimeric antigen receptor T-cell therapy: an international registry report. J Immunother Cancer. 2023;11:e005957.","journal-title":"J Immunother Cancer"},{"key":"2336_CR17","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","volume":"395","author":"F Zhou","year":"2020","unstructured":"Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in wuhan, China: A retrospective cohort study. Lancet 2020;395:1054\u201362.","journal-title":"Lancet"},{"key":"2336_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-31761-y","volume":"13","author":"TD Hughes","year":"2023","unstructured":"Hughes TD, Subramanian A, Chakraborty R, Cotton SA, Herrera M, Huang Y, et al. The effect of SARS-CoV-2 variant on respiratory features and mortality. Sci Rep. 2023;13:4503.","journal-title":"Sci Rep."},{"key":"2336_CR19","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/S0140-6736(22)00462-7","volume":"399","author":"T Nyberg","year":"2022","unstructured":"Nyberg T, Ferguson NM, Nash SG, Webster HH, Flaxman S, Andrews N, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Lancet. 2022;399:1303\u201312.","journal-title":"Lancet"},{"key":"2336_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102040","volume":"61","author":"Q Hofsink","year":"2023","unstructured":"Hofsink Q, Haggenburg S, Lissenberg-Witte BI, Broers AEC, van Doesum JA, van Binnendijk RS, et al. Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort study. EClinicalMedicine. 2023;61:102040.","journal-title":"EClinicalMedicine"},{"key":"2336_CR21","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adg9452","volume":"15","author":"TR M\u00fcller","year":"2023","unstructured":"M\u00fcller TR, Sekine T, Trubach D, Niessl J, Chen P, Bergman P, et al. Additive effects of booster mRNA vaccination and SARS-CoV-2 Omicron infection on T cell immunity across immunocompromised states. Sci Transl Med. 2023;15:eadg9452.","journal-title":"Sci Transl Med"},{"key":"2336_CR22","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1182\/bloodadvances.2022008338","volume":"7","author":"MA Gonzalez","year":"2023","unstructured":"Gonzalez MA, Bhatti AM, Fitzpatrick K, Boonyaratanakornkit J, Huang ML, Campbell VL, et al. Humoral and cellular responses to SARS-CoV-2 vaccines before and after chimeric antigen receptor-modified T-cell therapy. Blood Adv. 2023;7:1849\u201353.","journal-title":"Blood Adv"},{"key":"2336_CR23","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1182\/blood.2022016175","volume":"140","author":"D Atanackovic","year":"2022","unstructured":"Atanackovic D, Luetkens T, Omili D, Iraguha T, Lutfi F, Hardy NM, et al. Vaccine-induced T-cell responses against SARS-CoV-2 and its Omicron variant in patients with B cell-depleted lymphoma after CART therapy. Blood. 2022;140:152\u20136.","journal-title":"Blood"},{"key":"2336_CR24","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1038\/s41591-021-01386-7","volume":"27","author":"EM Bange","year":"2021","unstructured":"Bange EM, Han NA, Wileyto P, Kim JY, Gouma S, Robinson J, et al. CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nat Med. 2021;27:1280\u20139.","journal-title":"Nat Med"},{"key":"2336_CR25","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jtct.2022.10.010","volume":"29","author":"F Khawaja","year":"2023","unstructured":"Khawaja F, Papanicolaou G, Dadwal S, Pergam SA, Wingard JR, Boghdadly ZE, et al. Frequently Asked Questions on Coronavirus Disease 2019 Vaccination for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Recipients From the American Society for Transplantation and Cellular Therapy and the American Society of Hematology. Transpl Cell Ther. 2023;29:10\u201318.","journal-title":"Transpl Cell Ther"},{"key":"2336_CR26","doi-asserted-by":"publisher","DOI":"10.1111\/tid.14144","volume":"25","author":"E Kampouri","year":"2023","unstructured":"Kampouri E, Hill JA, Dioverti V. COVID-19 after hematopoietic cell transplantation and chimeric antigen receptor (CAR)-T-cell therapy. Transpl Infect Dis. 2023;25:e14144.","journal-title":"Transpl Infect Dis"},{"key":"2336_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22958-8","volume":"12","author":"S Dispinseri","year":"2021","unstructured":"Dispinseri S, Secchi M, Pirillo MF, Tolazzi M, Borghi M, Brigatti C, et al. Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival. Nat Commun. 2021;12:2670.","journal-title":"Nat Commun"},{"key":"2336_CR28","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1038\/s41591-022-01780-9","volume":"28","author":"B Killingley","year":"2022","unstructured":"Killingley B, Mann AJ, Kalinova M, Boyers A, Goonawardane N, Zhou J, et al. Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults. Nat Med. 2022;28:1031\u201341.","journal-title":"Nat Med"},{"key":"2336_CR29","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/cid\/ciad181","volume":"77","author":"M Mikulska","year":"2023","unstructured":"Mikulska M, Sepulcri C, Dentone C, Magne F, Balletto E, Baldi F, et al. Triple combination therapy with 2 antivirals and monoclonal antibodies for persistent or relapsed severe acute respiratory syndrome coronavirus 2 infection in immunocompromised patients. Clin Infect Dis. 2023;77:280\u20136.","journal-title":"Clin Infect Dis"},{"key":"2336_CR30","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1093\/cid\/ciac868","volume":"76","author":"ES Ford","year":"2023","unstructured":"Ford ES, Simmons W, Karmarkar EN, Yoke LH, Braimah AB, Orozco JJ, et al. Successful treatment of prolonged, severe coronavirus disease 2019 lower respiratory tract disease in a B cell acute lymphoblastic leukemia patient with an extended course of Remdesivir and Nirmatrelvir\/Ritonavir. Clin Infect Dis. 2023;76:926\u20139.","journal-title":"Clin Infect Dis"},{"key":"2336_CR31","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.jaci.2021.10.031","volume":"149","author":"LK Brown","year":"2022","unstructured":"Brown LK, Moran E, Goodman A, Baxendale H, Bermingham W, Buckland M, et al. Treatment of chronic or relapsing COVID-19 in immunodeficiency. J Allergy Clin Immunol. 2022;149:557\u201361.","journal-title":"J Allergy Clin Immunol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02336-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02336-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02336-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T09:04:48Z","timestamp":1724663088000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02336-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,23]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["2336"],"URL":"https:\/\/doi.org\/10.1038\/s41375-024-02336-1","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,23]]},"assertion":[{"value":"3 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There is no financial support for this work that could have influenced the outcomes described in the manuscript. However, several authors report a potential conflict of interest, which is described below. PL has received speaker fees for Kite\/Gilead and Pfizer, PB received advisory board and consultancy fees from Allogene, Amgen, BMS\/Celgene, Kite\/Gilead, Incyte, Miltenyi Biomedicine, Novartis, Nektar, Pfizer and Pierre Fabre, JM has received research support from Pfizer and Gilead and has served as a consultant or speaker for Gilead, Pfizer, MSD, Cidara, Mundipharma, F2G, Amplyx, Basilea, Shionoghi, Synexis and Takeda, AB has received fees for conference attendance and advisory boards from Kite\/Gilead and consultancy fees from NovartisSLP participated in advisory boards for Novartis, Kite-Gilead and Janssen, MJK reports honoraria from BMS\/Celgene, Kite\/Gilead, Novartis, and Roche; consulting or advisory roles for BMS\/Celgene, Kite Gilead, Miltenyi Biotec, Novartis, Takeda Pharmaceuticals, and Adicet Bio; and research funding from Kite Gilead, all to her institution. RC has received speaker fees for MSD, GSK, Novartis, Pfizer, Gilead and received advisory board and consultancy fees from MSD, Astellas, Roche; SM has received speaker\u2019s fees via his institution from Celgene\/BMS, Novartis, Janssen and Pfizer, received travel support and fees via his institution for participation in an expert panel from Kite\/Gilead, served on DSMB for Miltenyi and Mendes (via his institution), is the founder of SWECARNET (via his institution) and his spouse is the founder of ScientifyResearch.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Swedish central Ethical Board (EPM 2020-01731, 2021-04692). All patients gave informed consent to have their data reported to the EBMT registry.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate statement"}}]}}